XML 24 R14.htm IDEA: XBRL DOCUMENT v3.25.1
SEGMENT INFORMATION
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
SEGMENT INFORMATION SEGMENT INFORMATION
The Company operates and is managed as one business segment which derives revenue from activities related to the development and commercialization of innovative therapies for people with serious and life-threatening rare diseases and medical conditions.
The Company’s commercial organization is responsible for marketing our approved products worldwide. The Company’s research and development (R&D) organization is responsible for research and discovery of new product candidates and supporting the development and registration efforts for potential new products. The Company’s technical operations group is responsible for the development of manufacturing processes, supplying clinical drug product, and the manufacturing and distribution of the Company’s commercial products. The Company is also supported by corporate staff functions.
The Company’s Chief Executive Officer as the CODM manages and allocates resources to the operations of the total company by assessing the overall level of resources available and how to best allocate them to support the Company’s long-term company-wide strategic goals. In making this decision, the CODM uses consolidated financial information for the purposes of evaluating performance, allocating resources, setting incentive compensation targets and planning and forecasting for future periods.
The key measure of segment profit or loss used by the CODM to allocate resources and assess the Company's performance is its Consolidated Net Income, as reported on the Condensed Consolidated Statements of Comprehensive Income. The CODM's analysis includes a comparison to budgeted results. Segment assets provided to the CODM are consistent with those reported on the Condensed Consolidated Balance Sheets with particular emphasis on the Company's available liquidity including cash, cash equivalents, investments, accounts receivable and inventory.
The following table includes information about segment revenue, significant segment expenses, and segment measure of profitability:
Three Months Ended
March 31,
20252024
Total revenues$745,145 $648,833 
Less:
Cost of sales151,558 125,180 
R&D expenses
Research and early pipeline90,470 120,392 
Later-stage clinical programs14,291 — 
Marketed products53,970 84,595 
SG&A expenses
S&M expenses102,531 119,360 
G&A expenses103,585 106,546 
Other segment expense (income), net (1)
43,054 4,098 
Net income$185,686 $88,662 
(1)Other segment expense (income), net during the three months ended March 31, 2025 and 2024 include intangible asset amortization, interest income and expense, other income (expense) and income tax expense.
The following table presents Total Revenues and disaggregates Net Product Revenues by product.
Three Months Ended
March 31,
20252024
VOXZOGO$213,754 $152,889 
VIMIZIM188,346 192,520 
NAGLAZYME114,290 105,629 
PALYNZIQ93,269 75,709 
ALDURAZYME48,977 35,262 
BRINEURA40,362 39,047 
KUVAN25,136 35,910 
ROCTAVIAN10,510 849 
Total net product revenues734,644 637,815 
Royalty and other revenues10,501 11,018 
Total revenues$745,145 $648,833 
The Company considers there to be revenue concentration risks for regions where Net Product Revenues exceed 10% of consolidated Net Product Revenues. The concentration of the Company’s Net Product Revenues within the regions below may have a material adverse effect on the Company’s revenues and results of operations if sales in the respective regions experience difficulties. The table below disaggregates total Net Product Revenues by geographic region, which is based on patient location for the Company's commercial products sold directly by the Company, except for ALDURAZYME, which is distributed, marketed and sold exclusively by Sanofi worldwide.
Three Months Ended
March 31,
20252024
United States$241,694 $192,999 
Europe229,578 195,748 
Latin America88,282 78,594 
Rest of world126,113 135,212 
Total net product revenues marketed by the Company$685,667 $602,553 
ALDURAZYME net product revenues marketed by Sanofi48,977 35,262 
Total net product revenues$734,644 $637,815 
The following table illustrates the percentage of the Company’s total Net Product Revenues attributed to the Company’s largest customers for the periods presented.
Three Months Ended
March 31,
20252024
Customer A14 %14 %
Customer B12 11 
Customer C11 9 
Total37 %34 %
Concentration Information
On a consolidated basis, one customer accounted for 19% of the Company’s March 31, 2025 accounts receivable balance compared to December 31, 2024, when two customers accounted for 20% and 11% of the accounts receivable balance, respectively. As of March 31, 2025, and December 31, 2024, the accounts receivable balance for Sanofi included $105.0 million and $96.8 million, respectively, of unbilled accounts receivable, which becomes payable to the Company when the product is sold through by Sanofi. The Company does not require collateral from its customers, but does perform periodic credit evaluations of its customers’ financial condition and requires prepayments in certain circumstances.
The Company is mindful that conditions in the current macroeconomic environment, such as inflation, changes in interest and foreign currency exchange rates, natural disasters, geopolitical instability, impact of new or increased tariffs and escalating trade tensions, and supply chain disruptions, could affect the Company’s ability to achieve its goals. In addition, the Company sells its products in countries that face economic volatility and weakness. Although the Company has historically collected receivables from customers in certain countries, sustained weakness or further deterioration of the local economies and currencies may cause customers in those countries to delay payment or be unable to pay for the Company’s products. The Company believes that the allowances for doubtful accounts related to these countries, if any, are adequate based on its analysis of the specific business circumstances and expectations of collection for each of the underlying accounts in these countries. The Company will continue to monitor these conditions and will attempt to adjust its business processes, as appropriate, to mitigate macroeconomic risks to its business.